

Adaptimmune Therapeutics PLC
Form 6-K
November 13, 2015

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Form 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of November, 2015

Commission File Number: 001-37368

ADAPTIMMUNE THERAPEUTICS PLC

(Translation of registrant's name into English)

**101 Park Drive, Milton Park
Abingdon, Oxfordshire OX14 4RY
United Kingdom**

Edgar Filing: Adaptimmune Therapeutics PLC - Form 6-K

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes No

Other Events

On November 13, 2015, Adaptimmune Therapeutics plc (the Company) issued a press release reporting its financial results for its first quarter ended September 30, 2015. The press release includes the Company's unaudited condensed consolidated financial statements for the three months ended September 30, 2015, is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The Company management's discussion and analysis of financial condition and results of operations for the period is attached hereto as Exhibit 99.2 and is incorporated by reference herein. The information contained in Exhibits 99.1 and 99.2 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Exhibits

99.1 Adaptimmune Therapeutics plc Press Release and Unaudited Condensed Consolidated Financial Statements for the Three Months Ended September 30, 2015

99.2 Adaptimmune Therapeutics plc Management's Discussion and Analysis of Financial Condition and Results of Operations

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Adaptimmune Therapeutics plc

By:	/s/ Margaret Henry
Name:	Margaret Henry
Title:	Corporate Secretary

Date: November 13, 2015